The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment
| Autor: | Christou, G. A., Tellis, C. C., Elisaf, M. S., Tselepis, A. D., Kiortsis, D. N. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Piperidines/therapeutic use Middle Aged Obesity/*blood/complications/*therapy Fenofibrate/therapeutic use Retinol-Binding Proteins Plasma/*metabolism Pyrazoles/therapeutic use Apolipoproteins B/*blood Hypolipidemic Agents/therapeutic use Humans Female Diet Fat-Restricted Caloric Restriction Hypertriglyceridemia/*blood/etiology/*therapy |
| Popis: | We investigated the association between retinol-binding protein 4 (RBP(4)) and apolipoprotein B (ApoB)-containing lipoproteins. Obese or overweight, hypertriglyceridemic patients underwent the following interventions for 3 months: (1) Diet (n = 20), (2) Diet + fenofibrate (n = 18), (3) Diet + rimonabant (n = 8). Circulating RBP4 decreased during dietary treatment. The percentage change in RBP(4) was positively correlated with the percentage changes in very-low density lipoprotein cholesterol (r = .570, P = .02), low-density lipoprotein cholesterol ([LDL-C]; r = .605, P = .01), ApoB (r = .705, P = .007), and small dense LDL-C ([sdLDL-C]; r = .872, P < .001). The percentage change in RBP4 was the best predictor of the percentage changes in sdLDL-C and ApoB. Rimonabant treatment reduced RBP4, whereas fenofibrate increased RBP4 during the first month of therapy followed by a subsequent decrease. In conclusion, RBP4 may significantly influence the metabolic pathways responsible for changes in ApoB lipoprotein subspecies, thus RBP4 may be associated with cardiovascular disease risk. Angiology |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|